| 摘要 |
<p>Disclosed is a method for determining the sensitivity to irinotecan, SN-38 and/or a salt thereof, which can determine the therapeutic response of individual patients. Also disclosed is a novel means for treating cancer, which utilizes the method. Specifically disclosed is a method for determining the sensitivity to irinotecan, SN-38 and/or a salt thereof, which is characterized by measuring the expression level of AMD1 gene, CTSC gene, EIF1AX gene, C12orf30 gene, DDX54 gene, PTPN2 gene and TBX3 gene in a sample and calculating the best objective tumor response (%), the overall survival (day) or the progression-free survival (day) in accordance with formulae (1) to (3).</p> |
